Humacyte, Inc.
$0.68
▲ +4.41%
+$0.03
NASDAQ · Healthcare · Biotechnology
· price updated 9h ago
HUMA · NASDAQ · Healthcare · Biotechnology · price updated 9h ago
$0.68
▲ +4.41% · +$0.03 today
AI research · $0.68
Operating record
Capital structure
Valuation
Forward P/E
Price against expected earnings
No signal · Not enough data to judge
-
Price / sales
Value assigned to each sales dollar
Rich · Above 8x annual sales
87.39x
Price / FCF
Price against free cash generation
No signal · Not enough data to judge
-
EV / EBITDA
Operating value including debt
No signal · Not enough data to judge
-
Quality
ROIC
Return earned on invested capital
Weak · Below 8% return on capital
-71.5%
ROE
Profit generated from shareholder equity
Needs attention · Among weakest in sector
-409.5%
Debt / equity
Balance-sheet leverage
Needs attention · Among weakest in sector
5.72x
Current ratio
Short-term assets against liabilities
Strong · Comfortable short-term liquidity
3.93x
Selected financial data sourced from StockAnalysis and refreshed weekly. Figures may be delayed and are for research context, not investment advice.
| company | mkt cap | P/E | rev growth | score |
|---|---|---|---|---|
| $176.18M | - | - | 55 | |
| $10.69B | 18.4 | +23.5% | 78 | |
| $4.88B | 20.3 | +10.3% | 77 | |
| $31.49B | 32.9 | +15.5% | 77 | |
| $1.08T | 41.4 | +47.4% | 76 |
US stock research
Humacyte, Inc. trades on NASDAQ under the ticker HUMA. HUMA was +4.4% in the latest available session at $0.68. Its reported market value was $176.18M with a trailing P/E of 0.0. Latest reported revenue was $2.02M, with $-75.32M in net income.
Market snapshot updated Aug 3, 2026, 7:59 PM UTC.